DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Novo - 2 Ozempic - 2 Maggie Fick - 2 Kim Gradwell - 1 – - 1 John - 1 it's - 1 Rightangled - 1
Top related locs:
Britain United States England Europe Dudley , North Tyneside Novo London U.S
Top related orgs:
Diabetes - 2 National Health Service - 2 Social Care - 2 NHS - 2 Thomson - 2 Novo Nordisk - 1 King's College - 1 Department of Health - 1

Search resuls for: "Diabetes UK"


2 mentions found


☆ How well-off Brits still buy Ozempic online for weight loss
  + stars: | 2023-11-18 | by ( Maggie Fick | ) www.reuters.com   time to read: +12 min
NHS diabetes patients – including Gradwell, who went for weeks without full medication – pay nothing for their medication. The shortage persists even after Ozempic's manufacturer Novo Nordisk (NOVOb.CO) launched Wegovy, a semaglutide drug solely for weight loss, in September. Rightangled told Reuters it is within its rights to continue to prescribe Ozempic for weight loss. Two had stopped offering it for weight loss by October, but Rightangled continued to make it available as of Nov. 17, Reuters found. He said his oncologist said that while he could not prescribe Ozempic, it would be good for his health if he took it for weight loss.
Persons: Kim Gradwell, –, John, it's, Rightangled, Gradwell, Penny Ward, I've, Abdullah Sabyah, Ward, Juniper, Ben, Doctors, Novo, Ozempic, semaglutide, prescribers, Rightangled's Sabyah, Tyne wasn't, Gradwell's, Yaasir Mamoojee, We've, Maggie Fick, Marine Strauss, Charlotte Van Campenhout, Chad Terhune, Sara Ledwith, Josephine Mason Organizations: Diabetes, National Health Service, Novo Nordisk, King's College, Department of Health, Social Care, John, Reuters, Oxford University ., NHS, Alliance Healthcare, Alliance, Diabetes UK, NICE, semaglutide, Oxford University, General Pharmaceutical Council, Tyne, Thomson Locations: Dudley , North Tyneside, Britain, Novo, United States, London, U.S, England, Europe, Ozempic, Newcastle, Brussels, Los Angeles
☆ Analysis: Wegovy launch in UK may underline Novo's need to get ahead of Lilly
  + stars: | 2023-09-10 | by ( Maggie Fick | ) www.reuters.com   time to read: +5 min
A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. Studies have demonstrated more weight loss than with Wegovy. Novo's type 2 diabetes drug Ozempic has been on the market in Britain since 2019. A Lilly spokesperson declined to comment on Wegovy's launch or when exactly it would launch Mounjaro for diabetes treatment. Studies have shown that, used alongside exercise and lifestyle changes, Wegovy led to 15% weight loss over 68 weeks, while Mounjaro led to more than 22% over 72 weeks.
Persons: Victoria Klesty, Eli Lilly's, Wegovy, Lars Fruergaard Jorgensen, Novo, Lilly, Mounjaro, Ozempic, Eli Lilly, Maggie Fick, Alexander Smith, Catherine Evans Organizations: REUTERS, Wegovy, Economic Co, Development, Reuters, National Health Service, stoke, NHS, Britain's Department of Health, Social Care, Diabetes, UBS, Novo, Thomson Locations: Oslo, Norway, August31, Victoria, Britain, British, Danish, United States, Denmark, Germany, Europe, England
0 next >>
Total: 2